



THE PROBLEM

Despite gene therapy technologies advances, improvements are needed




THE SOLUTION

We combine the efficacy of viral and non viral insertional technologies with precision of modern programmable nucleases (cas9, ZNF)



DEVELOPMENT PLAN



KEY POINTS

Gene therapy is a dynamic market

NOVARTIS acquires AveXis for \$8.7B to transform care in SMA and expand position as a gene therapy and neuroscience leader. April 2018



THE PEOPLE

PROMOTERS



Marc Güell
Project Leader



Avencia Sánchez
Senior Researcher



Maria Pallarès
Junior Researcher

ADVISORS



George Church
Tech Dev Advisor



Francina Munell
Clinical Advisor



Pura Muñoz
Muscle Scientific Advisor

SUPPORT TEAM



Cinta Díez
UPF Business Shuttle



Gemma Guinart
UPF Ventures